IDO1

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Retrieved on: 
Tuesday, April 9, 2024
TME, Cell, Environment, Immunosuppression, IDO1, Tumor microenvironment, AACR, Neoplasm, Vaccination, Poster, Vaccine, Pharmaceutical industry

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
  • “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • Where high levels of IDO1 and PD-L1 expression were seen in the tumor microenvironment (TME), the IDO1 vaccine predominantly reduced myeloid-derived immune suppression, while the PD-L1 vaccine enhanced anti-tumor T-effector functions.
  • The poster can be found on the “ Posters & Publications ” page of the IO Biotech website and on the AACR website.

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
IO, TME, AACR, Vaccine, IDO1, Patient, Poster, PD-L1

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
  • The poster will include nonclinical data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study.
  • “We are excited with our new nonclinical data clearly demonstrating how the dual antigen vaccine IO102-IO103 differentially contribute to the anti-tumor effect: while IO102 treatment results in the reduction of the immune suppression in the TME, IO103 appears to impact by enhancement of T effector function,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • “These findings further support the potential that co-administration of the dual antigen vaccine IO102-IO103 can benefit patients due to its impact on two separate immune resistance pathways, IDO1 and PD-L1, respectively.”

IO Biotech Announces 2023 Third Quarter Results

Retrieved on: 
Monday, November 13, 2023
SCCHN, Neck, Research, Annual general meeting, Therapy, Head, CFO, Amgen, ESMO, Patient, IDO1, PFS, Vaccine, Pembrolizumab, Immunotherapy, Conference, ORR, Melanoma, MD, SITC, Lung cancer, Doctor of Philosophy, Congress, Neoplasm, Society, WCLC, Pharmaceutical industry, Cryptocurrency

“Our focus for 2023 has been to successfully execute multiple clinical trials for our novel, investigational therapeutic cancer vaccine, IO102-IO103.

Key Points: 
  • “Our focus for 2023 has been to successfully execute multiple clinical trials for our novel, investigational therapeutic cancer vaccine, IO102-IO103.
  • Encouraging preliminary data from this basket trial were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC) in September 2023 and at the ESMO Congress in October 2023.
  • General and administrative expenses were consistent at $5.8 million for the three months ended September 30, 2023 and 2022, respectively.
  • Cash and cash equivalents as of September 30, 2023, were $165.5 million, compared to $142.6 million at December 31, 2022.

EQS-News: Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

Retrieved on: 
Thursday, October 26, 2023
Knowledge, OTS, ASO, LNA, Asos, Doctor of Philosophy, IDO1, Oligonucleotide, TLR9, Kinetics, Patient, Infection, Fine chemical

The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • The poster 201: Characterization of immunostimulatory potential of LNA-modified antisense oligonucleotides was presented by Irene Riera Tur, PhD.
  • It could be shown that, among others, LNA-modified ASOs actually can induce activation of the human TLR9 pathway and downstream signaling.
  • “These data confirm our previous studies and convince us that we are on the right path to fully exploit the potential of ASOs.

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Pharmaceutical, Health, Oncology, IDO, Bladder cancer, BCG vaccine, PD-1, Risk, NMIBC, Patient, BMS, Phase, Toxicity, IDO1, BCG, Bristol Myers Squibb, PD-L1, Immunotherapy, KOL, Pharmaceutical industry, Medical device, Nivolumab

The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.
  • This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.
  • How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?
  • What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?

Bladder Cancer Disease Market Analysis Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Pharmaceutical, Health, Oncology, Clinical Trials, Avelumab, FGFR, NMIBC, Growth, Overalls, PD-1, Bladder cancer, Phase, Clinical trial, Control, IDO1, Dysuria, Population, Nivolumab, AstraZeneca, MUC, ADC, Cancer, Patient, Guideline, Urinary tract infection, Hematuria, Survival, FDA, Dietary supplement, Medical imaging, Fine chemical, Pharmaceutical industry, Durvalumab, Atezolizumab, Pembrolizumab, MIBC, Enfortumab vedotin

The "Disease Analysis: Bladder Cancer" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Bladder Cancer" report has been added to ResearchAndMarkets.com's offering.
  • Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally.
  • Bladder cancer is the fifth most common cancer in the US and Europe, and the ninth most common cancer worldwide.
  • PD-1/PD-L1 inhibitors remain the dominant class in the bladder cancer market in terms of patient share, and label expansion into earlier disease stages such as non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) will further grow the overall bladder cancer market.